Medulloblastoma Overview

Save information for later
Sign Up

Learn About Medulloblastoma

View Main Condition: Brain Tumor

What is the definition of Medulloblastoma?
Medulloblastoma is a type of brain tumor that occurs in the cerebellum. The cerebellum is important for coordination, particularly balance and movement. Medulloblastoma often spreads through cerebrospinal fluid (CSF) to other areas of the brain and the spinal cord. Medulloblastoma is the most common childhood malignant brain tumor. Roughly 250-500 new cases of medulloblastoma are diagnosed each year. 
What are the causes of Medulloblastoma?
The cause of medulloblastomas is still unknown. However, medulloblastomas generally tend to be more common in children than adults. Males are also more likely to develop medulloblastomas than females.
What are the symptoms of Medulloblastoma?
Common symptoms of medulloblastoma include headaches, nausea, vomiting, fatigue, poor coordination, dizziness, or difficulty walking. If the medulloblastoma has spread to the spinal cord, symptoms may also include back pain and difficulty controlling bowel and bladder functions. 
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Medulloblastoma?
Treatment for glioma may include surgery, radiation therapy, and/or chemotherapy. Surgery to remove as much of the tumor as possible is generally the first step in treating medulloblastoma. However, if a tumor is located near a sensitive area in the brain, surgery may not be possible at all. Radiation therapy often follows surgery for the treatment of medulloblastoma. Radiation therapy involves the use of high-energy beams, including X-rays or protons, to destroy tumor cells. Chemotherapy involves the use of drugs, either taken orally or injected through a vein, to kill tumor cells. Chemotherapy is often used in combination with radiation therapy.
Who are the top Medulloblastoma Local Doctors?
Experienced in Medulloblastoma
Dr. Aarati V. Rao
Pediatric Hematology Oncology | Pediatrics | Hospital Medicine
Experienced in Medulloblastoma
Dr. Aarati V. Rao
Pediatric Hematology Oncology | Pediatrics | Hospital Medicine
1600 Eureka Rd, 
Roseville, CA 
 (4.8 mi)
916-784-4000
Languages Spoken:
English

Aarati Rao is a Pediatric Hematologist Oncology specialist and a Pediatrics provider in Roseville, California. Dr. Rao and is rated as an Experienced provider by MediFind in the treatment of Medulloblastoma. Her top areas of expertise are Histiocytosis, Reticulohistiocytoma, Langerhans Cell Histiocytosis, Hepatoblastoma, and Bone Marrow Aspiration.

Experienced in Medulloblastoma
Dr. Richard L. Price
Neurosurgery
Experienced in Medulloblastoma
Dr. Richard L. Price
Neurosurgery

Regents Of The Univ Of Ca

3301 C St, Suite 1500, 
Sacramento, CA 
 (20.1 mi)
877-827-7463
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Richard Price is a Neurosurgery provider in Sacramento, California. Dr. Price and is rated as an Experienced provider by MediFind in the treatment of Medulloblastoma. His top areas of expertise are Spinal Stenosis, Glioblastoma, Astrocytoma, Microdiscectomy, and Cervical Disc Surgery.

 
 
 
 
Learn about our expert tiers
Learn More
Experienced in Medulloblastoma
Dr. Samuel F. Ciricillo
Neurosurgery | Neurology | Pediatric Neurology
Experienced in Medulloblastoma
Dr. Samuel F. Ciricillo
Neurosurgery | Neurology | Pediatric Neurology

Sutter Valley Medical Foundation

2800 L St, 
Sacramento, CA 
 (21.2 mi)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Samuel Ciricillo is a Neurosurgery specialist and a Neurologist in Sacramento, California. Dr. Ciricillo and is rated as an Experienced provider by MediFind in the treatment of Medulloblastoma. His top areas of expertise are Primitive Neuroectodermal Tumor (PNET), Posterior Fossa Tumor, Hydrocephalus, Awake Craniotomy, and Gastrostomy.

View All Doctors
How do I prevent Medulloblastoma?
There is no known way to prevent medulloblastomas. However, if you develop any symptoms common to a medulloblastoma, it is recommended to make an appointment with your doctor to be properly diagnosed.
What are the latest Medulloblastoma Clinical Trials?
A Phase I Study of Savolitinib in Recurrent, Progressive or Refractory Medulloblastoma, High-Grade Glioma, Diffuse Intrinsic Pontine Glioma, and CNS Tumors Harboring MET Aberrations
A Phase I Study of Savolitinib in Recurrent, Progressive or Refractory Medulloblastoma, High-Grade Glioma, Diffuse Intrinsic Pontine Glioma, and CNS Tumors Harboring MET Aberrations
Who is this study for: Patients with recurrent, progressive or refractory medulloblastoma, high-grade glioma, diffuse intrinsic pontine glioma, and CNS tumors harboring MET aberrations
Enrollment Status: Recruiting
Publish Date: February 26, 2025
Intervention Type: Procedure, Drug
Study Drug: Savolitinib
Study Phase: Phase 1

Summary: This phase I trial studies the side effects and best dose of volitinib in treating patients with primary central nervous system (CNS) tumors that have come back (recurrent) or does not respond to treatment (refractory). Volitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Phase I/II Study of Lutathera in Patients with Recurrent And/or Progressive High-Grade Central Nervous System Tumors and Meningiomas That Demonstrate Uptake on DOTATATE PET
Phase I/II Study of Lutathera in Patients with Recurrent And/or Progressive High-Grade Central Nervous System Tumors and Meningiomas That Demonstrate Uptake on DOTATATE PET
Who is this study for: Patients with Malignant Glioma, Embryonal Tumor
Enrollment Status: Recruiting
Publish Date: February 17, 2025
Intervention Type: Drug
Study Drug: LUTATHERA® (Lutetium Lu 177 Dotatate)
Study Phase: Phase 1/Phase 2

Summary: This study will evaluate the safety and efficacy of Lutathera (177Lu-DOTATATE) in patients with progressive or recurrent High-Grade Central Nervous System (CNS) tumors and meningiomas that demonstrate uptake on DOTATATE PET. The drug will be given intravenously once every 8 weeks for a total of up to 4 doses over 8 months in patients aged 4 to \<12 years (Phase I) or 12 to \

View All Clinical Trials
What are some Advocacy Organizations?
keep-punching-brain-cancer

Keep Punching supports patients, healthcare providers, and researchers in their fight to prevent and eradicate brain cancer and minimize treatment-related side effects that may adversely impact function and comfort.